<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col></col>
<col></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">CYP2C19 or CYP3A4 Inducers</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Decreased exposure of omeprazole when used concomitantly with strong inducers <content stylecode="italics">[see <linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">Clinical Pharmacology (12.3)</linkhtml>
</content>
<content stylecode="italics">].</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="underline">S</content>
<content stylecode="underline">t</content>
<content stylecode="underline">. John’s Wort, rifampin: </content>Avoid concomitant use with Omeprazole Delayed-Release Capsules <content stylecode="italics">[</content>
<content stylecode="italics">see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark26">W</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#_bookmark26">arnings and</linkhtml>
</content>
<content stylecode="italics"> <linkhtml href="#CIA74312L%20(redlines).docx#section_5_9">P</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_404e4be7-4b39-47e2-9053-59bbaa1a964a">recautions (5.9)</linkhtml>]</content>
<content stylecode="italics">.</content>
</paragraph>
<content stylecode="underline">Ritonavir-containing products:  </content>see prescribing information for specific drugs. </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">CYP2C19 or CYP3A4 Inhibitors</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Clinical Impact:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Increased exposure of omeprazole <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">C</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">l</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">n</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#CIA74312L%20(redlines).docx#section_12_3">i</linkhtml>
</content>
<content stylecode="italics">
<linkhtml href="#LINK_8f62c342-9bb1-4d39-bf67-e9d085f610e0">cal Pharmacology (12.3)</linkhtml>].</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
<content stylecode="italics">Intervention:</content> </td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="underline">V</content>
<content stylecode="underline">oriconazole</content>: Dose adjustment of Omeprazole Delayed-Release Capsules is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered.</paragraph> See prescribing information for voriconazole. </td>
</tr>
</tbody>
</table>